EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer

Sabrina N VandenHeuvel, Eric Chau, Arpita Mohapatra, Sameera Dabbiru, Sanjana Roy, Cailin O'Connell, Aparna Kamat, Biana Godin, Shreya A Raghavan iD

ACS Applied Bio Materials · 2024

DOI: 10.1021/acsabm.4c00076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2024. Verfasst von Sabrina N VandenHeuvel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Texas A&M University, 3120 TAMU, College Station, Texas 77843, United States. Hauptthemen laut MEDLINE: Immunotherapy, Macrophages, Nanoparticles, Ovarian Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NICHD NIH HHS, Texas A and M Engineering Experiment Station, Texas A and M University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyMacrophagesNanoparticlesOvarian NeoplasmsReceptors, ImmunologicFemaleHumansAntigens, DifferentiationBiocompatible MaterialsCD47 AntigenCell Line, TumorMaterials TestingParticle Size

Stichwörter der Autor:innen

CD47SIRPαimmunotherapymacrophagemetastasisnanotherapyovarian cancer

Substanzen

Antigens, DifferentiationBiocompatible MaterialsCD47 AntigenCD47 protein, humanReceptors, ImmunologicSIRPA protein, human

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Texas A&M University, 3120 TAMU, College Station, Texas 77843, United States.
  • Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, Texas 77030, United States.
  • School of Engineering Medicine, Texas A&M University, 1020 Holcombe Boulevard, Houston, Texas 77030, United States.
  • Division of Gynecologic Oncology, Houston Methodist Hospital, 6550 Fannin Street, Houston, Texas 77030, United States.
  • Department of Obstetrics and Gynecology, Houston Methodist Hospital, 6550 Fannin Street, Houston, Texas 77030, United States.
  • Houston Methodist Neal Cancer Center, 6445 Main Street, Houston, Texas 77030, United States.

ORCID-Profile: Shreya A Raghavan

Förderung

  • NCI NIH HHS
  • NICHD NIH HHS
  • Texas A and M Engineering Experiment Station, Texas A and M University
  • National Institutes of Health
  • Dr. and Mrs. Kaplan Gynecologic Cancer Fund

Zitieren

APA

VandenHeuvel, S. N., Chau, E., Mohapatra, A., Dabbiru, S., Roy, S., O'Connell, C., Kamat, A., Godin, B., & Raghavan, S. A. (2024). Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.4c00076

Vancouver

VandenHeuvel SN, Chau E, Mohapatra A, Dabbiru S, Roy S, O'Connell C, et al. Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer. ACS Applied Bio Materials. 2024. doi:10.1021/acsabm.4c00076

BibTeX
@article{VandenHeuvel2024,
  author = {VandenHeuvel, Sabrina N and Chau, Eric and Mohapatra, Arpita and Dabbiru, Sameera and Roy, Sanjana and O'Connell, Cailin and Kamat, Aparna and Godin, Biana and Raghavan, Shreya A},
  title = {Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer},
  journal = {ACS Applied Bio Materials},
  year = {2024},
  doi = {10.1021/acsabm.4c00076}
}
Kostenlos starten →